The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: A randomized, double-blind, placebo-controlled trial

Human Reproduction

Volumn 25, Issue 4, 2010, Pages 995-1004

  Busso, Cristiano ^a   Fernández Sánchez, Manuel ^b   García Velasco, Juan Antonio ^c   Landeras, José ^d   Ballesteros, Augustín ^e   Muñoz, Elkin ^f   González, Sandra ^g   Simón, Carlos ^a   Arce, Joan Carles ^h   Pellicer, Antonio ^a  

^a IVI Valencia   (Spain)

^b IVI Sevilla   (Spain)

^c IVI Madrid   (Spain)

^d IVI Murcia   (Spain)

^e IVI Barcelona   (Spain)

^f IVI Vigo   (Spain)

^g IVI Bilbao   (Spain)

^h Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Dopamine agonists; OHSS prevention; Quinagolide; Randomized controlled trial

Indexed keywords

PLACEBO; QUINAGOLIDE; RECOMBINANT CHORIONIC GONADOTROPIN;

ADULT; ARTICLE; ASCITES; BIRTH RATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; HUMAN; HYDROCEPHALUS; INCIDENCE; KIDNEY POLYCYSTIC DISEASE; LIVE BIRTH; LOW DRUG DOSE; MULTICENTER STUDY; NAUSEA; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PREGNANCY; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; SYNDACTYLY; TREATMENT DURATION; TRISOMY 21; URETER DUPLICATION; VOMITING;

EID: 77949943219     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deq005     Document Type: Article

References (23)

1. Alvarez C, Alonso-Muriel I, Garćia G, Crespo J, Bellver J, Simón C, Pellicer A. Implantation is apparently unaffected by the dopamine agonist Cb2 when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. Hum Reprod 2007a;22:3210-3214.
2. Alvarez C, Mart́i-Bonmat́i L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, Simón C, Pellicer A. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 2007b;92:2931-2937.
3. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829.
4. B́usso C, Garcia-Velasco J, Gómez R, Alvarez C, Simón C, Pellicer A. Update on prediction and management of OHSS Prevention of OHSS\dopamine agonists. Reprod Biomed Online 2009;19:43-51.
5. Carizza C, Abdelmassih V, Abdelmassih S, Ravizzini P, Salgueiro L, Salgueiro PT, Jine LT, Nagy P, Abdelmassih R. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study. Reprod Biomed Online 2008;17:751-755.
6. Devroey P, Boostanfar R, Koper NP, Mannaerts BMJL, Ijzerman-Boon PC, Fauser BCJM on behalf of the ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009; doi: 10.1093/humrep291, Advance Access published 14 August 2009.
7. Enskog A, Henriksson M, Unander M, Nilsson L, Brännström M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril 1999;71:808-814.
8. Ferraretti AP, Gianaroli L, Diotallevi L, Festi C, Trounson A. Dopamine treatment for severe ovarian hyperstimulation syndrome. Hum Reprod 1992;7:180-183.
9. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-440.
10. Gómez R, Simón C, Remoh́i J, Pellicer A. Vascular endothelial growth factor receptor-2-activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 2002;143:4339-4348.
11. Gómez R, Simón C, Remoh́i J, Pellicer A. Administration of moderate and high doses of gonadotrophins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod 2003; 68:2164-2171.
12. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J, Remohi J, Simon C, Pellicer A. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology 2006;147:5400-5411.
13. Kars M, Delgade V, Holman ER, Feelders RA, Smit JWA, Romijn JA Bax JJ, Pereira AM. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 2008; 93:3348-3356.
14. Lyons CA, Wheeler CA, Frishman GN, Hackett RJ, Seifer DB, Haning RV Jr. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors. Hum Reprod 1994; 9:792-799.
15. Mathur RS, Akande AV, Keay SD, Hunt LP, Jenkins JM. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000;73:901-907.
16. Martin NM, Tan T, Meeran K. Dopamine agonists and hyperprolactinaemia. Br Med J 2009;338:554-555.
17. w versus Metrodin) in in-vitro fertilization). Hum Reprod 1995; 10:2534-2540.
18. Papanikolaou EG, Tournaye H, Verpoest W, Camus M, Vernaeve V, Van Steirteghem A, Devroey P. Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profile. Hum Reprod 2005; 20:636-641
19. Pregnancy Outcomes Working Group of the FDA Pregnancy Labeling Taskforce in the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research at the Food and Drug Administration. Reviewer Guidance. Evaluating the risks of drug exposure in human pregnancies. 2005; http://www.fda.gov/ downloads/ScienceResearch/SpecialTopics/ WomensHealthResearch/ UCM133359.pdf.
20. Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the athogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update 1997;3:255-266.
21. Roth BL. Drugs and valvular heart disease. NEJM 2007;356:6-7.
22. Whelan JG III, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883-896.
23. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356:39-46.